Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 6Carcinoid Tumor 5Neoplasms 4Carcinoma 3Vipoma 2Neoplasm Metastasis 2Intestinal Obstruction 2Carcinoma, Islet Cell 2Somatostatinoma 1Recurrence 1Prostatic Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Peritoneal Neoplasms 1Malignant Carcinoid Syndrome 1Lymphangiomyoma 1Lymphangioleiomyomatosis 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Diarrhea 1Chylous Ascites 1Chylothorax 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Ascites 1Adenoma, Islet Cell 1

Interventions

Temozolomide 2Everolimus 2Capecitabine 2Bevacizumab 2regorafenib 1pazopanib 1motesanib diphosphate 1batifiban 1Sorafenib 1Panobinostat 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Fentanyl 1Doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glucagonoma × Octreotide × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡